Abstract Pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy that has an extremely poor prognosis despite the use of intensive chemotherapy. Recently, treatment of BPDCN with bone marrow transplantation (BMT) using myeloablative conditioning has been reported to increase survival in adults. We report a 9-year-old girl with cutaneous BPDCN who was successfully treated with combination chemotherapy followed by BMT using reduced intensity conditioning (RIC), without any adverse complications. The success of this treatment regimen suggests that BMT with RIC may be a feasible option for treating children with cutaneous BPDCN.
Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy, which was previously known as blastic natural killer (NK)-cell leukemia/lymphoma, agranular CD4? NK-cell leukemia, or CD4?/ CD56? hematodermic neoplasm [1] . According to the 2008 revision of the World Health Organization (WHO) classification of myeloid disorders and leukemia, BPDCN is considered to be a myeloid neoplasm [1] . It is a clinically aggressive tumor known to be derived from the precursors of plasmacytoid dendritic cells (pDCs) (CD123?) with a high frequency of cutaneous and bone marrow involvement [2] . The overall prognosis is dismal, with a median overall survival of 12-14 months [3] . Recent studies suggest that the best treatment options include intensive, acute lymphoblastic leukemia (ALL)-like chemotherapy, followed by hematopoietic stem cell transplantation (SCT) in the first complete remission (CR) [4] . Recently, in adult case, it has been observed that skin-restricted BPDCN shows no better outcome than primarily disseminated, hence, aggressive management including SCT should be considered despite the fact that BPDCN may initially appear as a localized skin [5] . After all, the treatment including indication of SCT and recommended conditioning regimen of BPDCN being initially limited to the skin remain controversial and not standardized. We described a girl with BPDCN, which exclusively involved the skin at presentation. Knowledge of pediatric BPDCN is especially limited, with only a few case reports described in the literature; further, there are no clinical reports of pediatric BPDCN treated with reduced-intensity stem-cell transplantation (RIST). In this report, we describe the case of a 9-year-old girl with cutaneous BPDCN who was treated with RIST.
Case Report
A 9-year-old girl with a 2-month history of a gradually enlarging subcutaneous mass (1 9 1 cm) in her left forearm was referred to our hospital for treatment. Physical examination revealed a palpable solid, painless, 3 9 3 cm subcutaneous mass (Fig. 1) . No hepatosplenomegaly or lymphadenopathy were found. Laboratory data revealed a normal complete blood count, chemistry panel, and cerebrospinal fluid cell count. The titer of soluble interleukin-2 receptor (sIL-2R) was 346 U/mL. A pretreatment whole body PET/CT scan showed increased 3H-2-fluoro-2-deoxy-D-glucose (FDG) uptake within the subcutaneous mass on the left forearm (Fig. 2) . PET/CT was performed after biopsy, therefore it only showed local surgical stress and no metastasis. A biopsy specimen showed tumor cells with irregular nuclei and eosinophilic inclusion bodies diffusely invading the subcutaneous fatty tissue from the dermis. Neoplastic cells were positive for CD4, CD56, CD123, and TdT (Fig. 3) , and negative for CD3, CD5, CD7, CD20, MPO, and TIA-1, indicating BPDCN. No bone marrow involvement was found morphologically. The subcutaneous mass completely resected was relapsed immediately. After local re-excision of the lesion, the patient received systemic lymphoblastic lymphoma-type chemotherapy including prednisolone, dexamethasone, cyclophosphamide, L-asparagine, cytarabine, vincristine, daunorubicin, methotrexate, and mercaptopurine according to Phase II clinical trial of limited stage lymphoblastic lymphoma (ALB-NHL03) by Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). After four cycles of chemotherapy, bone marrow transplantation (BMT) was performed from a HLA-DR one-locus mismatched unrelated donor (allele-level, 7/8 match) due to a paucity of compatible related or unrelated donors. Since the patient underwent BMT in the state of full remission, prevention against treatment-related early and late toxicities was carried out by using RIST. Table 1 shows conditioning regimens. Graft-versus-host disease (GVHD) prophylaxis included tacrolimus and short course methotrexate. A total of 1.3 9 10 8 /kg BM nucleated cells were transplanted. The early post-transplantation period was uneventful, however, the patient presented with fever and rash on the face and extremities including palm on day 10. The rash was erythematous with pruritus and spread to over 50 % of the body surface. She had mild diarrhea but not icteric. It was diagnosed as grade 2 GVHD. Treatment with methylprednisolone was effective against symptoms of GVHD. Engraftment was achieved on day 19. At day 29, GVHD was improved but mild pruritus became persistent. At day 42, CMV antigenemia appeared and treated by administration of ganciclovir. Although she had mild hepatic dysfunction, it was improved immediately. At day 63, CMV antigenemia was improved and ganciclovir was stopped. She didn't have other infections. After that, she has been achieved complete donor chimerism. At day 104, she was discharged without any complication. After 29 months, the patient was found to have no GVHD and was in full remission without any apparent toxicity.
Discussion
BPDCN has been known to be an entity derived from the precursors of pDCs. However, the origin of pDCs has been controversial. It seems that both pDCs and common DCs may be derived from a common DC precursor [6] . On the other hand, some studies suggest that pDCs can originate from a common lymphoid progenitor [7] . We have described a pediatric case of BPDCN. Notably, this case with lesion restricted to the skin was treated performing BMT using RIST in the status of full remission. BPDCN usually occurs in older patients and is characterized by a high frequency of manifestations in the skin, lymph node, and bone marrow [2, 8, 9] . The phenotypic appearance of the cutaneous lesions is variable, ranging from local to diffuse. The overall prognosis is dismal, with a median overall survival of 12-14 months [3]. To date, the treatment of BPDCN is not standardized owing to extremely poor prognosis. Classical chemotherapy regimens for acute myeloid leukemia have been disappointing, as the initial response has most often been followed by early relapse [6, 10, 11]. Several studies suggest that patients can be successfully treated with combination chemotherapy for ALL followed by hematopoietic SCT [4, 12, 13] . Dalle et al. reported a case study of BPDCN in 47 patients ranging in age from 8 to 96 years. In total, BMT was performed in ten patients. The difference in overall survival between patients with BMT (mean, 31.3 months) and those without BMT (mean, 12.8 months) was highly significant (P = 0.0018) [6] . The study confirmed that an aggressive treatment strategy that included BMT was necessary to ensure improved clinical outcome. [14] . In children who underwent SCT, the overall survival was 67 % (4/6 cases), compared with 74 % (14/19 cases) in non-transplanted patients [14] . Importantly, the two patients who died despite receiving SCT had not received initial combination chemotherapy and concerned about the possibility of not full remission before SCT. Jegalian et al. also reported 11 of the 18 children with cutaneous BPDCN survived (61 % survival; median follow up, 60 months) [14] . Additionally, Sagashita et al. reported 3-year overall survival was 57.4 ± 10.9 % in a total of 32 cases of pediatric BPDCN for whom follow up information was available [15] . SCT was applied in first or second remission to two of eight patients who lacked skin involvement, and 6 of 23 patients with cutaneous disease [15] . For these reports of CR and long-term survival without SCT in children, in contrast to BPDCN in adults, where the long-term survival depends on SCT in the first CR, BPDCN in children may be clinically less aggressive. SCT may be reserved for children who relapse and achieve a second remission. Although, it has been reported that BPDCN cases with skin involvement had more unfavorable outcome than with leukemia and a lack of skin involvement [14] [15] [16] . Sagashita et al. also reported the overall survival in eight children with BPDCN without cutaneous disease at presentation was significantly higher than the value in children with skin involvement [15] . But this report included not only BPDCN with lesion restricted to the skin. A summary of eight cases of pediatric BPDCN being initially limited to the skin is shown in Table 2 [17] [18] [19] [20] [21] . With only a few case reports of pediatric BPDCN being initially limited to the skin, treatment remains controversial and not standardized, especially. SCT has been considered as an alternative treatment strategy in case of failure of chemotherapy. But we selected SCT following combination chemotherapy due to early local relapse and poor prognosis of BPDCN in adults and with lesion restricted to the skin. Since BPDCN in children is rare, the efficacy and necessity of SCT for treating pediatric BPDCN has also been controversial. Our current case study suggests that consecutive treatment of combination chemotherapy following SCT may be effective for pediatric patients with BPDCN. In addition, we used RIST for the possibility of prevention of treatment-related early and late toxicities. In recent years, reduced intensity conditioning (RIC) regimens have been demonstrated to safe and efficacious for adult hematologic malignancies [22] . Since most RIC regimens use relatively low doses of chemotherapy, transplant-related morbidity and mortality are low [23] . Whereas relapse rates after RIC may be higher, reductions in transplant-related morbidity and mortality have generally compensated for this, and several studies have shown outcomes comparable with myeloablative conditioning (MAC) [24] . Dietrich et al. suggested that allogeneic (allo) SCT with RIC may be an effective treatment against BPDCN in elderly patients up to 70 years [19] . In this study, a MAC regimen was used in 74 % (n = 25) and RIC regimen was used in 26 % of the cases (n = 9) [3] . Disease free survival, and overall survival was significantly better in patients who received the MAC regimen than in those who received the RIC regimen. The poor outcome of patients treated with RIC was largely due to a high nonrelapse mortality (NRM) rate; none of the patients treated with RIC were able to achieve prolonged disease control owing to early relapse or death. However, patients treated with RIC were significantly older than those treated with MAC (median age, 62 vs. 36 years; P = 0.005), and the high mortality rate in the RIC group was due to NRM, rather than relapse [3] . In this study two groups has significant difference of median age, therefore, we can't make a simple comparison of outcome between MAC and RIC. It is also difficult to conclude the efficacy of using RIC to treat BPDCN, especially in children. The results of a phase 2 trial of RIC transplantation concluded that favorable outcomes could be achieved for children and adolescents with hematologic malignancy in remission at ransplantation [25] . Indeed, if BPDCN in children was clinically less aggressive than that in adults, RIST may be an effective treatment option for prevention against treatment-related early and late toxicities, especially in patients who are in remission. Treatment related late toxicities such as infertility and growth deficiency and secondary malignant neoplasms have been reported in patients who received BMT with MAC. RIC regimens might be the preservation of fertility and the reduced risk of secondary malignant neoplasms [18] . Hence, the MAC regimen is preferably best avoided in children as for late toxicities. Although the role of RIC regimens in pediatric cancer treatment remains unclear [25] , the possibility of prevention against treatment-related early and late toxicities is considerable. Further studies are required to determine the necessity of BMT and the efficacy of BMT with RIST, as well as the most appropriate treatments for children with BPDCN, particularly being initially limited to the skin. Conditioning regimens included 3 Gy total body irradiation (day 7), fludarabine 25 mg/m 2 (95 days, from day 6 to day 2), melphalan 70 mg/m 2 (92 days, day 6 and day 2), and rabbit antithymocyte globulin 2.5 mg/kg (92 days, day 3 and day 2) 
